tradingkey.logo

BRIEF-Zenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives

ReutersFeb 5, 2025 12:36 PM

- Zenas Biopharma Inc ZBIO.O:

  • ZENAS BIOPHARMA : TOPLINE RESULTS FROM PHASE 2 TRIAL IN RELAPSING MULTIPLE SCLEROSIS (MOONSTONE) EXPECTED IN Q3 2025

  • ZENAS BIOPHARMA :TOPLINE RESULTS FROM PIVOTAL PHASE 3 TRIAL IN IMMUNOGLOBULIN G4-RELATED DISEASE (INDIGO) EXPECTED YEAR-END 2025

Source text: ID:nGNX3GBN3c

Further company coverage: ZBIO.O

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI